Insight, China's Pharmaceutical Industry

Company Medical Device

Johnson & Johnson Secures FDA Approval for Dual Energy THERMOCOOL SMARTTOUCH SF Platform, First Single-Catheter Solution Combining Radiofrequency and Pulsed Field Ablation

Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk

Fineline Cube Jul 9, 2026

AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for...

Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026

Xenovector, a pioneering biotechnology company in xenotransplantation, has announced a deep strategic cooperation with Jilin...

Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) and Tigermed Consulting Co., Ltd. (SHE: 300347, HKG:...

Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026

China’s National Health Commission (NHC) has released the National Essential Medicines List (NEML) 2026 Edition,...

Company Medical Device

Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement

Fineline Cube Jul 8, 2026

Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its proprietary transvenous tricuspid valve replacement system,...

Others

Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721

Fineline Cube Jul 8, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Fineline Cube Jul 8, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that its clinical trial application...

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Fineline Cube Jul 8, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its proprietary SHR-4685 has...

Others

AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy

Fineline Cube Jul 8, 2026

Wainua (eplontersen sodium injection), jointly developed by AstraZeneca plc (NYSE: AZN) and Ionis Pharmaceuticals (NASDAQ:...

Others

OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model

Fineline Cube Jul 8, 2026

OTR Therapeutics announced a strategic collaboration with LG Chem (KRX: 051910) to jointly accelerate the...

Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Fineline Cube Jul 8, 2026

Hangzhou Qihan Biotech Engineering Life (“Qihan Biotech”) announced that its QT-019C cell injection has received...

Company Drug

Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis

Fineline Cube Jul 8, 2026

Insilico Medicine (HKG: 3696) announced the initiation of a Phase 3 clinical trial (CTR20262475, NCT07687459)...

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026

Transcenta Holding Limited (HKG: 6628) announced it will return select collaborative products to Eli Lilly...

Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced the formal establishment of a Joint Laboratory...

Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Fineline Cube Jul 8, 2026

Nanjing Pharmaceutical Co., Ltd. (SHA: 600713) announced that its holding subsidiary, Nanjing Pharmaceutical Group Qianglian...

Company Drug

LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors

Fineline Cube Jul 8, 2026

LTZ Therapeutics announced that its second drug candidate, LTZ-232, has received Investigational New Drug (IND)...

Company Digital

Peking University Third Hospital Introduces World’s First PTH Replacement Therapy Palopegteriparatide Through Beijing Rare Disease Pilot Zone

Fineline Cube Jul 8, 2026

Peking University Third Hospital has officially introduced palopegteriparatide, the world’s first and only approved parathyroid...

Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026

MindRank, a clinical-stage AI-native drug discovery company, announced the completion of a $52 million Series...

Company Drug

Shanghai Stexo Biotechnology Secures NMPA Clinical Approval for STX11101 Extracellular Vesicle Therapy in Acute Liver Failure

Fineline Cube Jul 8, 2026

Shanghai Stexo Biotechnology Co., Ltd. announced that its proprietary extracellular vesicle drug STX11101 injection, derived...

Insight, China's Pharmaceutical Industry

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Johnson & Johnson Secures FDA Approval for Dual Energy THERMOCOOL SMARTTOUCH SF Platform, First Single-Catheter Solution Combining Radiofrequency and Pulsed Field Ablation

AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement

Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy

OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors

Peking University Third Hospital Introduces World’s First PTH Replacement Therapy Palopegteriparatide Through Beijing Rare Disease Pilot Zone

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Shanghai Stexo Biotechnology Secures NMPA Clinical Approval for STX11101 Extracellular Vesicle Therapy in Acute Liver Failure

You Missed

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors